glp 1 dallas GLP-1 use rising rapidly among U.S. adolescents, young adults: Newsroom IRL Advertising Is Helping GLP-1

Frequently Asked Questions How often should I get NAD+ IV therapy

DSIP is a research peptide and is not FDA-approved for human use in the United States

Process Insight The bioprocess segment is the highest contributor to the market and is expected to grow at a CAGR of 5.3% during the forecast period

Contact your insurance provider for coverage and copay details

The lure of the obesity drug market was the impetus in a bidding war between Pfizer and Novo Nordisk for acquiring Metsera, a New York-based clinical-stage bio/pharmaceutical company focused on obesity and cardiometabolic diseases, with Pfizer emerging victorious with a successful offer, worth up to $10 billion, in a deal that closed last month (November 2025)